Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  XBiotech announced ... study being conducted in the US for its ... Human™ monoclonal antibody therapy, is being evaluated in ... complicated with cachexia. The primary endpoint of the ... treated patients to a control population provided only ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... in its catalogue: Acute Heart Failure ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart ... Summary GlobalData,s clinical trial report, "Acute ... provides data on the Acute Heart Failure clinical ...
(Date:9/2/2014)... 2014 According to a ... "Latin America Home Healthcare Market (By Device Types: ... Mobility Assist Devices and Medical Supplies; By Services: ... and Unskilled Home Healthcare Services) - Industry Analysis, ... 2020" the Latin American Home Healthcare market was ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6
... 27 Tengion, Inc. (Nasdaq: TNGN ), ... its first Analyst and Investor Meeting which was held ... and discussions of milestones and key data for the ... archive of the event and presentation materials will be ...
... DEL REY, Calif., Oct. 27 Prostate Oncology Specialists, ... sites in the nation to treat advanced prostate cancer ... therapeutic class known as autologous cellular immunotherapies.  PROVENGE was ... for the treatment of men with asymptomatic or minimally ...
Cached Medicine Technology:Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs 2Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs 3Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs 4Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs 5Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE 2Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE 3Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE 4
(Date:9/2/2014)... Angeles, CA (PRWEB) September 02, 2014 ... article on its website titled “Why You Should Wash ... than 80 percent of the global population breathes air ... and particles of pollution lodge in the skin’s pores ... body’s natural barrier to free radicals that may cause ...
(Date:9/2/2014)... groundwork for their own spread throughout the body by ... signals, according to a new report by Johns Hopkins ... Nature Communications , the researchers describe animal and ... molecules released by breast cancer cells. These molecules cause ... nodes to produce proteins called CCL5 and VEGF. CCL5 ...
(Date:9/2/2014)... By Kathleen Doheny ... -- The U.S. obesity epidemic is a driving force behind ... new study. Researchers looked at data from five national ... the increase in diabetes over time could be explained by ... in U.S. adults. The investigators found that the prevalence ...
(Date:9/2/2014)... News) -- A leading group of oncologists has released ... of advanced breast cancer. HER2-negative breast tumors ... the HER2 protein, the American Society of Clinical Oncology ... Almost 80 percent of women with advanced breast cancer ... this guideline, our aim is to improve both the ...
(Date:9/2/2014)... research on sleep apnea, tonsillectomies, hearing loss, head ... be presented in Orlando, FL, September 21-24, at ... the American Academy of OtolaryngologyHead and Neck Surgery ... nose, throat, head and neck physicians in the ... presented were released today, and are available online ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... women with a common thyroid problem may have a ... ,Studies in the past have shown that one of ... Although animal studies found mammary gland cells responded to ... in the relationship between thyroid hormone and breast cancer. ...
... allergen found in the air in many inner-city homes ... in children say researchers. ,According to researchers children ... allergy-causing substance found in mouse urine that is circulating ... developing allergic sensitivity to mice, just as it does ...
... live their lives by their sports drinks and energy drinks ... athletic achievements. //According to a study published in the January ... dental enamel is caused by bottled lemonade, sports drinks and ... enamel by these drinks are as much as 11 times ...
... there are actually scientific reasons why children may be ... strong // sweet tooth. Researchers found variation in a ... and adults. Age and culture also contribute to taste ... the study researchers compared taste sensitivity and food-related behaviors ...
... to evaluate the effect of diseases on contact with children ... were less likely to get the kind of affection other ... HIV-positive parents report avoided certain types of physical contact with ... to their children or pick up infections from the kids ...
... gum disease are more likely to suffer from atherosclerosis, or ... attack // or stroke shows latest research . ... mouths of 657 people who had no history of heart ... used to identify atherosclerosis, was also measured. People with a ...
Cached Medicine News:
...
For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
Medicine Products: